CliffBio
biologic

Cytogam

Cytomegalovirus Immune Globulin Intravenous (Human)

Loss of exclusivityApril 2002projected — 12-year biologic exclusivity estimate
CompanyKamada Ltd. →See this company's full patent-cliff portfolio

Drug detail

Brand nameCytogam
Active ingredientCytomegalovirus Immune Globulin Intravenous (Human)
Strength2.5G/50ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalApril 1990
Marketing statusRx

More from Kamada Ltd.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Cytogam patent cliff — loss of exclusivity April 2002 | CliffBio